Margaret Martin, PharmD

Metabolic Syndrome in Bipolar Depression With Lumateperone (ITI-007): A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. This post hoc, pooled ...

Margaret Martin , PharmD;

01/19/2023

Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: Evaluation of Extrapyramidal and Motor Symptoms in Late-Phase Clinical Trials

This analysis evaluated extrapyramidal symptoms (EPS) across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week...

Margaret Martin , PharmD;

10/26/2023